Evidence map›Paper›PMID 32393494›Full record

ArticleAntimicrobial agents and chemotherapy2020

Preserving Vascular Integrity Protects Mice against Multidrug-Resistant Gram-Negative Bacterial Infection.

Teclegiorgis Gebremariam, Lina Zhang, Sondus Alkhazraji, Yiyou Gu, Eman G Youssef, Zongzhong Tong, Erik Kish-Trier, Ashok Bajji, Claudia V de Araujo, Bianca Rich and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Teclegiorgis GebremariamThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Lina ZhangThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Sondus AlkhazrajiThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Yiyou GuThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Eman G YoussefThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Zongzhong TongA6 Pharmaceuticals, Salt Lake City, Utah, USA.
Erik Kish-TrierA6 Pharmaceuticals, Salt Lake City, Utah, USA.
Ashok BajjiA6 Pharmaceuticals, Salt Lake City, Utah, USA.
Claudia V de AraujoDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Bianca RichDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Samuel W FrenchThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Dean Y LiA6 Pharmaceuticals, Salt Lake City, Utah, USA.
Alan L MuellerA6 Pharmaceuticals, Salt Lake City, Utah, USA.
Shannon J OdelbergDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Weiquan ZhuDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Ashraf S IbrahimThe Lundquist Institute for Biomedical Innovations at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA ibrahim@lundquist.org.ORCID 0000-0003-3787-8530
University of Utah · USArrien Pharmaceuticals (United States) · USUCLA Medical Center · USUniversity of California, Los Angeles · USBeni-Suef University · EG

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens SupplementR01AI141202 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2019 to 2023
$5.7M
Novel vascular guidance mechanismsR01HL077671 · NHLBI · UNIVERSITY OF UTAH · PI ZHU, WEIQUAN (WENDY) · 2004 to 2017
$4.3M
New Therapies to Restore Vascular Integrity During SepsisR01HL130541 · NHLBI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J, WEYRICH, ANDREW S · 2016 to 2020
$3.7M
ARF6 Inhibitors for Treatment of Acute Lung InjuryR44HL127886 · NHLBI · NAVIGEN, INC. · PI MUELLER, ALAN L · 2017 to 2018
$1.7M
Identifying a nodal point for G alpha q signaling in eye diseaseR01CA202778 · NCI · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J · 2016 to 2020
$1.7M
Targeting ARF6, A Convergence Point For Multiple Pathways of Diabetic RetinopathyR01EY025342 · NEI · UNIVERSITY OF UTAH · PI ZHU, WEIQUAN (WENDY) · 2015 to 2019
$1.7M
The Role of the Vasculature in the Pathogenesis of ArthritisR01AR064788 · NIAMS · UNIVERSITY OF UTAH · PI ODELBERG, SHANNON J · 2013 to 2017
$1.6M
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative InfectionsR33AI119339 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2017 to 2019
$1.4M
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative InfectionsR21AI119339 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2015 to 2016
$361k
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA202778NEI NIH HHS R01 EY025342NHLBI NIH HHS R01 HL077671NHLBI NIH HHS R01 HL130541NHLBI NIH HHS R43 HL127886NHLBI NIH HHS R44 HL127886NIAID NIH HHS R01 AI063503NIAID NIH HHS R01 AI141202NIAID NIH HHS R21 AI119339NIAID NIH HHS R33 AI119339NIAMS NIH HHS R01 AR064788
6 · The paper itself

Abstract

The rise in multidrug-resistant (MDR) organisms portends a serious global threat to the health care system with nearly untreatable infectious diseases, including pneumonia and its often fatal sequelae, acute respiratory distress syndrome (ARDS) and sepsis. Gram-negative bacteria (GNB), including

Indexed as

Acinetobacter baumanniiGram-Negative Bacterial InfectionsADP-Ribosylation Factor 6AnimalsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialGram-Negative BacteriaMiceMicrobial Sensitivity TestsPseudomonas aeruginosaADP-Ribosylation Factor 6Anti-Bacterial AgentsARF6 protein, humanArf6 protein, mouseAcinetobacter baumanniiARF6drug resistanceGram-negative bacteriaKlebsiella pneumoniaelipopolysaccharideLPSmultidrug resistancePseudomonas aeruginosasepsisvascular permeability

Identifiers

PMID32393494
PMCPMC7526831
OpenAlexW3024286624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.